JP6068484B2 - トランスサイレチン関連アミロイドーシスの新規療法 - Google Patents
トランスサイレチン関連アミロイドーシスの新規療法 Download PDFInfo
- Publication number
- JP6068484B2 JP6068484B2 JP2014536290A JP2014536290A JP6068484B2 JP 6068484 B2 JP6068484 B2 JP 6068484B2 JP 2014536290 A JP2014536290 A JP 2014536290A JP 2014536290 A JP2014536290 A JP 2014536290A JP 6068484 B2 JP6068484 B2 JP 6068484B2
- Authority
- JP
- Japan
- Prior art keywords
- ttr
- pharmaceutically acceptable
- comt
- inhibitor
- transthyretin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- MIQPIUSUKVNLNT-UHFFFAOYSA-N Cc(cc1)ccc1C(c(cc1O)cc([N+]([O-])=O)c1O)=O Chemical compound Cc(cc1)ccc1C(c(cc1O)cc([N+]([O-])=O)c1O)=O MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11382326 | 2011-10-24 | ||
| EP11382326.4 | 2011-10-24 | ||
| PCT/EP2012/070945 WO2013060668A1 (en) | 2011-10-24 | 2012-10-23 | New therapy for transthyretin-associated amyloidosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530842A JP2014530842A (ja) | 2014-11-20 |
| JP2014530842A5 JP2014530842A5 (https=) | 2015-12-10 |
| JP6068484B2 true JP6068484B2 (ja) | 2017-01-25 |
Family
ID=47076222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014536290A Active JP6068484B2 (ja) | 2011-10-24 | 2012-10-23 | トランスサイレチン関連アミロイドーシスの新規療法 |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US9610270B2 (https=) |
| EP (1) | EP2770988B1 (https=) |
| JP (1) | JP6068484B2 (https=) |
| KR (1) | KR102017354B1 (https=) |
| CN (1) | CN103889407B (https=) |
| AU (2) | AU2012327275B2 (https=) |
| BR (1) | BR112014009322B1 (https=) |
| CA (1) | CA2852808C (https=) |
| CL (1) | CL2014000893A1 (https=) |
| CY (1) | CY1118151T1 (https=) |
| ES (1) | ES2593038T3 (https=) |
| IL (1) | IL231907B (https=) |
| MX (2) | MX385516B (https=) |
| PL (1) | PL2770988T3 (https=) |
| PT (1) | PT2770988T (https=) |
| RU (2) | RU2747536C2 (https=) |
| SG (2) | SG11201401215VA (https=) |
| WO (1) | WO2013060668A1 (https=) |
| ZA (1) | ZA201402546B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2747536C2 (ru) * | 2011-10-24 | 2021-05-06 | Сом Инновэйшн Биотек, С.Л. | Новая терапия транстиретин-ассоциированного амилоидоза |
| DK3185957T3 (da) * | 2014-08-29 | 2022-08-29 | Alnylam Pharmaceuticals Inc | Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis |
| EP3275433A1 (en) | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| US20210008209A1 (en) * | 2018-03-12 | 2021-01-14 | Corino Therapeutics, Inc. | Combination therapy for ttr amyloidosis |
| EP3976017A4 (en) * | 2019-05-31 | 2023-06-14 | Plex Pharmaceuticals, Inc. | PHARMACOLOGICAL SUBSTANCES FOR THE TREATMENT OF PROTEIN AGGREGATION DISEASES OF THE EYE |
| JP2023549533A (ja) * | 2020-11-13 | 2023-11-27 | プレックス ファーマスーティカルズ，インク | 眼の状態を処置するための薬理剤 |
| CN114324693B (zh) * | 2022-01-14 | 2023-01-13 | 大连博源医学科技有限公司 | 一种血液中转甲状腺素蛋白(ttr)四聚体浓度测定的预处理方法和检测方法 |
| WO2024081554A2 (en) * | 2022-10-10 | 2024-04-18 | Corino Therapeutics, Inc. | Modified release tolcapone formulations |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744368A (en) | 1993-11-04 | 1998-04-28 | Research Foundation Of State University Of New York | Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR) |
| WO1998027972A2 (en) | 1996-12-23 | 1998-07-02 | Texas A & M University | Anti-amyloidogenic agents |
| FI20002044A0 (fi) | 2000-09-15 | 2000-09-15 | Orion Yhtymae Oyj | Comt-entsyymiä estäviä naftaleenijohdannaisia |
| PT1372682E (pt) | 2001-03-15 | 2012-08-03 | Proteotech Inc | Catequinas para o tratamento de fibrilogénese em doença de alzheimer, doença de parkinson, amiloidose αa sistémica e outras perturbações amiloides |
| WO2004065614A2 (en) | 2002-01-29 | 2004-08-05 | Protemix Corporation Limited | Suppression of cytotoxic protein conformers |
| US20040175382A1 (en) | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| AU2005215136A1 (en) | 2004-02-20 | 2005-09-01 | Novartis Ag | DPP-IV inhibitors for treating neurodegeneration and cognitive disorders |
| CN1921856A (zh) * | 2004-02-20 | 2007-02-28 | 诺瓦提斯公司 | 用于治疗神经变性疾病和认知障碍的dpp－iv抑制剂 |
| KR20070032700A (ko) * | 2004-05-20 | 2007-03-22 | 폴드알엑스 파마슈티칼스, 인크. | 트랜스티레틴을 안정화하고 트랜스티레틴 미스폴딩을억제하기 위한, ２-((헤테로)아릴)-벤즈옥사졸 화합물 및유도체, 그리고 조성물 및 방법 |
| WO2006026555A2 (en) | 2004-08-30 | 2006-03-09 | Seo Hong Yoo | Neuroprotective effect of solubilized udca in focal ischemic model |
| GB2429645A (en) | 2006-03-10 | 2007-03-07 | Sekhsaria Chemicals Ltd | Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent |
| US20120016037A1 (en) | 2006-07-24 | 2012-01-19 | Frank Toppo | Method for prevention and treatment of Alzheimers |
| GB0718718D0 (en) | 2007-09-25 | 2007-11-07 | Pentraxin Therapeutics Ltd | Compound and use thereof |
| DE102010010572A1 (de) | 2010-03-08 | 2011-09-08 | Mahle International Gmbh | Trockenseparator |
| RU2747536C2 (ru) * | 2011-10-24 | 2021-05-06 | Сом Инновэйшн Биотек, С.Л. | Новая терапия транстиретин-ассоциированного амилоидоза |
-
2012
- 2012-10-23 RU RU2017119539A patent/RU2747536C2/ru active
- 2012-10-23 EP EP12778323.1A patent/EP2770988B1/en active Active
- 2012-10-23 PT PT127783231T patent/PT2770988T/pt unknown
- 2012-10-23 KR KR1020147010767A patent/KR102017354B1/ko active Active
- 2012-10-23 US US14/353,459 patent/US9610270B2/en active Active
- 2012-10-23 JP JP2014536290A patent/JP6068484B2/ja active Active
- 2012-10-23 SG SG11201401215VA patent/SG11201401215VA/en unknown
- 2012-10-23 BR BR112014009322-9A patent/BR112014009322B1/pt active IP Right Grant
- 2012-10-23 MX MX2017006182A patent/MX385516B/es unknown
- 2012-10-23 PL PL12778323T patent/PL2770988T3/pl unknown
- 2012-10-23 MX MX2014004863A patent/MX347784B/es active IP Right Grant
- 2012-10-23 WO PCT/EP2012/070945 patent/WO2013060668A1/en not_active Ceased
- 2012-10-23 ES ES12778323.1T patent/ES2593038T3/es active Active
- 2012-10-23 AU AU2012327275A patent/AU2012327275B2/en not_active Ceased
- 2012-10-23 RU RU2014114930A patent/RU2623062C2/ru active
- 2012-10-23 SG SG10201609933WA patent/SG10201609933WA/en unknown
- 2012-10-23 CA CA2852808A patent/CA2852808C/en active Active
- 2012-10-23 CN CN201280051812.8A patent/CN103889407B/zh not_active Expired - Fee Related
-
2014
- 2014-04-03 IL IL231907A patent/IL231907B/en active IP Right Grant
- 2014-04-08 ZA ZA2014/02546A patent/ZA201402546B/en unknown
- 2014-04-09 CL CL2014000893A patent/CL2014000893A1/es unknown
-
2016
- 2016-09-20 CY CY20161100934T patent/CY1118151T1/el unknown
-
2017
- 2017-03-02 US US15/448,054 patent/US10045956B2/en active Active
- 2017-04-21 AU AU2017202670A patent/AU2017202670B2/en not_active Ceased
-
2018
- 2018-08-13 US US16/101,882 patent/US10449169B2/en active Active
-
2019
- 2019-09-12 US US16/569,055 patent/US10786473B2/en active Active
-
2020
- 2020-08-28 US US17/005,893 patent/US11564899B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6068484B2 (ja) | トランスサイレチン関連アミロイドーシスの新規療法 | |
| JP7242945B2 (ja) | 細胞生存率を向上させるための組成物およびその使用方法 | |
| US20210069139A1 (en) | Stabilization of transthyretin tetramers in biological fluids | |
| NZ623267B2 (en) | New therapy for transthyretin-associated amyloidosis | |
| HK1198432B (en) | Therapy for transthyretin-associated amyloidosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151020 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151020 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160701 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160930 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161202 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161222 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6068484 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |